Supply of Adenosine Injection (Pharmaceutical Product)

The contract involves the procurement and delivery of one unit of Adenosine Injection, a sterile, FDA-regulated pharmaceutical product, to a military medical facility located in Alaska. The supplier must ensure full compliance with current Good Manufacturing Practices (cGMP) and adhere to all federal labeling standards to guarantee safety, potency, and regulatory acceptance. Delivery is specified under FOB Destination terms, meaning the vendor bears all risks and costs until the product arrives at the military facility in Alaska, ensuring traceability and accountability through the entire shipping process. This subcontract is issued under the NAICS code 325412 for pharmaceutical and biological product manufacturing, and is managed by the Defense Logistics Agency on behalf of the Department of Defense, reflecting its alignment with federal medical supply protocols for critical care pharmaceuticals. The contract supports operational readiness by securing a vital injectable medication used in emergency cardiac care, with strict adherence to quality and documentation standards to meet military healthcare requirements. Although no solicitation number, set-aside designation, or point of contact is provided, the official contract record is accessible via the DIBBS system under the referenced award and delivery identifiers. This procurement underscores the Defense Logistics Agency’s commitment to maintaining reliable access to life-saving pharmaceuticals in remote and mission-critical locations, ensuring that U.S. military medical facilities have uninterrupted supply of essential drugs that meet the highest regulatory and operational norms.